Research items
Erdal Can Alkoclar currently works at the Biotechnological R&D, Mas Pharmaceutical Investment Corp.. Erdal Can Alkoclar is a Turkish inventor, scientist and investor. Alkoclar is the co-founder and running president of Yesilalkoclar R&D company. He is the sole inventor of 143 applied and 282 pending patents; 44 of them being in current PCT protection. Alkoclar also is the rights holder and applicant of the largest amount of pharmaceutical ingredient patents as sole individual in Turkey. Alkoclar has won a 4th price which is given by Turkish Patent Institute for having the 4th largest number of applied patents in 2014 and The Scientist of the Year Awards for Turkey in 2016 and 2019
Current institution
Mas Pharmaceutical Investment Corp.
Biotechnological R&D
Current position
Head of Department
Skills and Expertise
Awards & Achievements
Award · Jun 2019
Scientist of the Year for Turkey
Award · May 2016
Scientist of the Year for Turkey
Award · Apr 2015
Turkish Patent Awards
Followers (2)View all
Following (1)View all
ETH Zurich
Research Items (33)
BACKGROUND A Formulation consisting of 2 Dioscin and 2 Glucopyranoside Derivatives with Simultaneous GHRH Stimulative and T3 mRNA Expression Enhancimg Features. OBJECTIVE Anti Aging METHODS GH/T3 Optimization RESULTS Approved in Vitro CONCLUSIONS Endogenous GH and T3 Optimization is the an efficient method for combating age related Senility and Fatigue Symptoms
A Pro-dopaminergic formulation that works via elevating cAMP expression in Substantia Nigra region and stimulating structural regeneration.
The invention is related to a composition developed for treating spinal cord injury. Current Status of Technique Spinal cord is a part of central nervous system, which extends from neck to sacrococcygeal zone in a bone structure, also referred as spine, and the cord has a central canal extending along the cord. Spinal cord controls involuntary behaviors and reflexes. Recently, there is no efficient treatment of spinal cord injury. If post-traumatic spinal cord injury or any other cerebrospinal dysfunction cannot be improved with surgery or physiotherapy, efforts are made to increase expression of spinal cAMP with PDE4 inhibiting agents and thus, it is tried to regenerate spinal neuron cells. Studies are conducted on growth factors, such as NGF, neurotropin and IGF-1, which effectively trigger production of nerve cells. Again, in the recent invention TR200800693 titled "treatment method of demyelinating diseases and conditions", the formula, lapos;in N-(pyridyl)-1H-indol-1-amines offer combination of gating features for both potassium and calcium channes. Those compounds are useful for treatment of demyelinating diseases and condidtions such as multiple sclerosis, spinal cord injury, traumatic brain injury and stroke. Those compounds are also useful in rehabilitation of Stroke, Urine Bladder Irritation and Dysfunction and for treatment of neuropathic pain and chemokin-induced pain.
An Anti-Asthenic Formulation designed to support Mitochondrial integrity and optimum function via elevating mitochondrial amino acid uptake and modulating interleukin levels.
The invention relates to a topical composition for increasing the speed of wound healing.
The invention is related to a nootropic composition. Current Status of Technique Recently, nootropic drugs are used to prevent cerebral cortex against hypoxia based on cerebral effects and to reinforce cognitive functions, such as memory, attention and consciousness, without exerting sedative or psychostimulating effects. Available nootropic compounds extend in a wide spectrum, including agents supporting permeability of cell membrane, acetlycholine esterase inhibitors, glutamata inhibitors and dopamine receptor agonists. Acetylcholine esterase inhibitors function by suppressing the acetylcholine esterase, the enzyme reducing acetyl choline. The compounds, used for this purpose, lose functionality in long term due to tolerance and the chronic suppression may reduce concentration of nicotinic receptors and finally, they cause irreversible hepatic and renal damage in long term. Due to recycling of acetylcholinesterase, this enzyme is produced highly above normal limits following suppression period, resulting with hazardous decrease of acetyl choline level. Although racetame derivatives are efficient and multi-functional compounds, they may lead to depletion of acetyl choline, if they are not taken with an efficient choline derivative, and accordingly, they are nootropic treatment derivatives, which may lead to decreased release of growth hormone, secondary to reduction of release of acetyl choline, and exert negative effects on thyroid functions and risk of inducing edema in long term.
The invention relates to a composition formed for the treatment of allergic reactions. State of the Art Histamine is a substance, which is present in most human and animal cells and causes the reactions called allergy when it goes out of the cell for various reasons. Levvis, at the experiments he conducted with histamine on animals early in this century, noticed the occurrence of a red dot in the skin at the site of injection, a wide red zone around this dot and a swelling in the form of a wide edema around said zone (triple response). In addition, when he injected histamine at higher doses to guinea pigs and rabbits, he observed the occurrence of a shock resembling the tissue damage. The cell lysis has been accepted to increase the production of histamine especially in the lungs and the skin and initiate the antigen-antibody reaction. The substances that cause general tissue damage (trypsin, peptone, snake or bee venom, detergents), macromolecular substances (horse serum, dextran), endotoxins and some drugs (epinephrine, morphine, codeine, tubocurarine, etc.) release histamine and cause allergic reactions. Subsequent researches have shown that histamine acts like a local hormone and reduces the blood pressure as well as playing a role in the transmission in the nervous system (neurotransmitter) and affecting some receptors (Hl and H2 receptors). Accordingly, some of the histamine-associated effects such as the increased gastric secretion mediated by H2 receptors, increased heart rate and itching may be eliminated with some medicaments. The substances that prevent the effects of histamine are referred to as antihistamines. Antihistamines prevent the emergence of such reactions, rather than treating them. In cases such as severe allergy and anaphylactic shock, the patient is 1 5 10 15 20 25 30
Novel Formulation with GLUT4 and GLP-1 enhancing Properties
The invention relates to a composition formed for the prevention of geriatric cachexia. State of the Art The weakness resulting from the old age may be classified by the reduction of the anaerobic capacity (muscle strength) as well as deconditioning and the structural deteriorations in the body structure. Reduction in the muscle strength and the lifting force, loss of elasticity and strength from the muscle tissues and connective tissues, decrease in bone density and bone organic density, reduction in the continuity of physical power and in the lung capacity, weakening of the cardiac muscle and the reduction of the oxygen use efficiency, circulatory disorders and cardiovascular insufficiencies resulting from the weakening of the cardiac muscle, urinal and fecal incontinence caused by the loss of neuromuscular efficiency, inability to completely recover following the fractures and the condition of being unable to live without support may be listed as the examples of geriatric cachexia. Pro-cholinergic drugs, hormone therapy and exercise may be mentioned as the examples of the currently existing treatments for this condition. Centrophenoxine (meclofenoxate) treatment provides increase in the muscle strength and condition improvement in the elder and partially regulates some endocrinal parameters. The growth hormone and anabolic steroid supplement yield quite good results at low doses, but they may cause various symptoms from the prostate enlargement to the prostate cancer, from the colon cancer to the heart attack, from diabetes to acromegaly in case of overdose or of failure to monitor the tolerance.
The invention relates to a hypothermic composition formed for reducing the fever. State of the Art Hypothermia is a condition in which the normal body temperature of 37°C drops below 35°C. In general, it is triggered by such conditions as exposure to rain, wind, snow or cold water. The human body performs heat exchange with its environment and is influenced by this exchange according to the temperature of the environment. In case the environment is hot, the body heats up, whereas it becomes cool if the environment is cold. For example, when a human bathes naked in the cold water, the body quickly gives heat to the water and thus the body losses heat. When the heat loss starts in a human, the standard heat level of the body drops. Loss of consciousness occurs at 32-35°C and the death occurs in cases of drop below this range. According to current practice, the following are applied to an individual exposed to hypothermia: The patient may be administered a liquid at room temperature, but since this is a hypothermic condition, a liquid at a temperature of 40-45°C must be preferred. The liquids not containing blood and dextrose may be heated in a microwave device. Dextrose-containing saline solutions must be preferred and ringer's lactate must not be used. The reason is that lactate is not metabolized in case of hypothermia. Gastric, peritoneal and bladder irrigation or lavement may be performed with liquids at 45°C. Water bath at 40°C is a good method provided that the water temperature is frequently controlled. However, the cardiac monitoring and the i.v. treatment of the patient are quite difficult with this method. It is also possible to warm the blood by way of hemodialysis. Pleural lavage via thoracostomy is another method possible to be performed. The warmed air may be provided by means of a 1 5 10 15 20 25 30
The invention relates to a composition formed for the use of methylsalidroside and ginsenoside rg3 in the treatment of the alcohol addiction. State of the Art Today, tricyclic antidepressants, racetam derivatives, psychological group therapies and meetings are employed as the possible methods for the treatment of alcohol addiction. The use of antidepressants and other psychotropic drugs usually aggravates the condition in the short term, and irreversibly aggravates the already existing depression caused by the alcohol addiction. Although partially successful results are obtained from the racetam derivatives, the alcohol addiction may relapse when their use is stopped. Group therapies suffer the instability of participation caused by the discomfort that the individuals feel about their situation. As a result, the presence of the need for a composition formed for the use of methylsalidroside and ginsenoside rg3 in the treatment of the alcohol addiction and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art. Object of the Invention In order to eliminate the disadvantages of the state of the art, an object of the invention is to enable the body to repair the imbalance of dopamine and serotonin release in the body within a short time.
The invention relates to a composition (methylprotobiocide, protopanaxatriol protopanaxadiol, Hibiscus Rosa Sinensis and Circuiligo Orchioides extracts) for the symptomatic treatment of MS and ALS diseases and the treatment of the associated neuromuscular damage.
The invention is related to a composition of ginsenoside RG3, which is developed for treating depression. Current Status of Technique Recently, available treatment modalities of depression include meditation, group therapies and drugs exerting effects over serotonin metabolism, as medications. Tricyclic antidepressants has very severe side effects, such as severe mental disorders and irreversible tendency to suicide since they impair cyclic production of serotonin and they early exhaust limited serotonin production potential of body. Another risk-bearing alternative, use of narcotic agents)such as amphetamine derivatives) generate positive outcomes in short term, but tolerance develops in short time and such agents lead to injury of dopaminergic system, and thus, in addition to side effects of tricyclic antidepressants mentioned above, they may cause to violence tendency and general aggressivity. In conclusion, the need to a composition for using ginsenoside RG3 in treatment of depression and inadequacy of current solutions lead to the necessity to make a development in the technical field.
The invention relates to a composition formed for treating anxiety and depression.
The invention relates to a composition formed for increasing the athletic performance. State of the Art Today, the performance is involved in every field of daily life and in all the circumstances where there is interaction with the other people. Our current perception of performance is shaped by our past experiences. For a high level of performance, some cognitive and psychological abilities peculiar to the subject of performance must be provided to the individual. Every human can do better and show superior performance. Currently, there are many formulations applied for the improvement of athletic performance in sports. These involve the plant or animal products and artificial or natural products containing the supplement of protein, amino acid, vitamin, etc. Since
The invention relates to a protopanaxtriol composition formed for the treatment of the prostate cancer and the benign prostatic hyperplasia. State of the Art Today, the prostate cancer is a disease that occurs with the development of cancer in the prostate, which is a secretory gland associated with the male reproduction system. The cancer develops when the prostate cells undergo change and begin to increase in an uncontrolled manner. These cells may in time spread from the prostate to the other regions of the body, especially the bones and the lymph (metastasis). The prostate cancer may lead to such symptoms as pain, difficulty in urination and erectile dysfunction. On the other hand, these symptoms are observed only in the advancing stages of the disease. In addition, today the simultaneously elevated levels of the testosterone and estrogen hormones underlie the cases of prostate cancer and benign prostatic hyperplasia. In fact, if testosterone is not converted to DHT by way of alpha reductase interaction, it interacts with aromatase to be converted to estradiol, which (the simultaneously elevated levels of testosterone and estrogen) in turn leads to the prostatic hyperplasia, and the prostate cancer in more serious conditions. The existing therapies involve the use of alpha reductase blockers and the estrogen supplements. Such therapies usually fail to yield satisfactory results and they may also cause permanent fertility disorders and sexual dysfunctions. The same active agents also result in gynecomastia (enlargement of breast tissue) and feminization.
The invention relates to a composition formed for the treatment of attention and concentration deficit disorders. The invention relates in particular to a composition formed for the use of alpha-methyl-tyrosine ethyl ester, dimethylsalidroside and puerarin derivative for the treatment of attention and concentration deficit disorders.
The invention relates to a composition comprising dioscin derivatives and 98-E, eurycoma longifolia and cissus extracts for treating the neuroendocrinal damage caused by the autoimmune diseases.
A Formulation formulated to treat thyrogenic enzyme expression defects.
The invention relates to a composition formed for the use of low-dose isoflavones in the treatment of andropause. State of the Art For the treatment of andropause; the testosterone replacement therapy, DHEA therapy and growth hormone replacement therapy are currently employed. Testosterone therapy blocks the production of natural testosterone, suppresses the release of LH FSH, and causes the aromatase expression to increase and the externally administered testosterone to be converted to the estrogen derivatives. Although the DHEA supplement yields very good results at low doses, since each individual has different endocrinal responses, the duration of use and the daily dose may not be adjusted very efficiently and the benign prostatic hyperplasia, elevated estrogen and thyroid imbalances may result in the medium term. The growth hormone supplement, as in the intake of testosterone, causes the suppression of GHRH hormone that stimulates the production of the growth hormone and may, in case of overdose, exhibit undesirable side effects such as thyroid problems, carpal tunnel syndrome, heart enlargement and acromegalic symptoms.
The invention relates to a composition formed for the use of ginsenoside rg3 and methylprotodioscin in the treatment of the sperm production defects.